Phase 4 Trial, Dexmedetomidine, Myocardial Injury, Hangzhou
Summary
A Phase 4 clinical trial registered on ClinicalTrials.gov (NCT07549282) is studying dexmedetomidine for myocardial injury in surgical patients. The single-center trial is conducted in Hangzhou, China. This registry entry documents the trial's existence and basic parameters as part of the ClinicalTrials.gov Phase 4 trial database.
About this source
GovPing monitors ClinicalTrials.gov - Phase 4 Trials for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 17 changes logged to date.
What changed
A new Phase 4 clinical trial registration has been entered into the ClinicalTrials.gov database. The trial NCT07549282 is investigating dexmedetomidine for myocardial injury outcomes in surgical patients.
Healthcare providers and clinical investigators involved in perioperative cardiac care should be aware of this trial. Pharmaceutical companies manufacturing dexmedetomidine may find this trial relevant to their post-marketing surveillance obligations.
Archived snapshot
Apr 28, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Show glossary
Related changes
Get daily alerts for ClinicalTrials.gov - Phase 4 Trials
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov - Phase 4 Trials publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.